STARTUP PROFILE

Ampa Health

COUNTRY
USA
FOUNDED
2022
CATEGORY
Neuromodulation
Developing a portable transcranial magnetic stimulation system to expand access to clinically validated neuromodulation treatments for mental health disorders.
Visit website →
Neurofounders Insights
$   Funding   -
Seed
MODALITY
TMS
FORM FACTOR
External device
INTERFACE DEPTH
Non-invasive
INDICATION
Psychiatry
TARGET USER
Patients
REGULATORY STAGE
FDA cleared (510k)
Ampa Health is positioned around expanding TMS access by miniaturizing the delivery system into a portable form factor, addressing the key bottleneck of clinic-bound infrastructure that limits current TMS adoption. With FDA clearance and seed-stage funding, it sits at an early commercial stage in a TMS market otherwise dominated by large-footprint systems from BrainsWay and Magstim.
Mentioned in Market Notes
MOST RECENT COVERAGE
#
1
Tracking Neurotech Startups
1 May – 26 May 2026

Ampa raised an oversubscribed financing (approximately $17M) led by Morningside Ventures, Trimera Capital, Neta Foundation, Jake Collective, and Tim Ferriss, bringing total funding to more than $35M. The capital will accelerate rollout of its FDA-cleared Ampa One portable TMS system, already deployed across more than 30 states. The system costs $3,000 per month, fits in a car trunk, and can be operated after a few hours of training. Demand has doubled every quarter since launch.

Articles featuring
Ampa Health